The European Commission has opened an antitrust investigation into Sanofi for allegedly running a misleading communication campaign that disparaged CSL Seqirus's Fluad flu vaccine while promoting its own Efluelda vaccine in Germany and France.
Regulators are concerned that Sanofi portrayed Fluad as inferior to Efluelda despite national and European recommendations supporting the CSL vaccine for vulnerable patients, and that this conduct may amount to anticompetitive disparagement and abuse of a dominant market position.
The probe follows unannounced raids on Sanofi offices in September 2025, and the company has stated it is confident it complied with competition law and is cooperating fully with the European Commission.
Sources:
EU Commission opens antitrust probe into Sanofi's flu vaccine campaign
Sanofi invited to settle EU antitrust probe into flu vaccine (update*)
Commission opens disparagement investigation into Sanofi
European antitrust regulators probe Sanofi for allegedly disparaging a rival flu vaccine
Brussels, Belgium, June 26, 2026 (AFP) - EU hits France's Sanofi ...
Sanofi Suspected by EU of Disparaging a Flu Vaccine Rival
EU Launches Antitrust Probe Into Sanofi Over Allegedly Misleading ...
Sanofi Probed by EU Over Flu Vaccine Marketing - Morningstar
Sanofi says under investigation by European Commission over vaccines
Sanofi Raided by EU in ‘Disparagement' Antitrust Case
Sanofi Probed by EU Over Flu Vaccine Marketing
EU opens antitrust probe over Sanofi flu vaccine marketing.
Sanofi faces EU antitrust probe into vaccine business - pharmaphorum